Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Modeling the Effects of Vorinostat In Vivo Reveals both Transient and Delayed HIV Transcriptional Activation and Minimal Killing of Latently Infected Cells

23 Oct 2015

Abstract excerpt

Recent efforts to cure human immunodeficiency virus type-1 (HIV-1) infection have focused on developing latency reversing agents as a first step to eradicate the latent reservoir. The histone deacetylase inhibitor, vorinostat, has been shown to activate HIV RNA transcription in CD4+ T-cells and alter host cell gene transcription in HIV-infected individuals on antiretroviral therapy. In order to understand how...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to HIV/AIDS drug development and treatment
Share to HIV/AIDS Research and Interventions
Share to HIV Research and Treatment

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 26496627
DOI: 10.1371/journal.ppat.1005237

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Modeling the Effects of Vorinostat In Vivo Reveals both Transient and Delayed HIV Transcriptional Activation and Minimal Killing of Latently Infected CellsPMID 26496627Read ↗

Interval dosing with the HDAC inhibitor vorinostat effectively reverses HIV latencySemantic proximity Read ↗

Dynamics of HIV Latency and Reactivation in a Primary CD4+ T Cell ModelSemantic proximity Read ↗

Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapySemantic proximity Read ↗

Ex vivo analysis identifies effective HIV-1 latency–reversing drug combinationsSemantic proximity Read ↗

HIV latency: experimental systems and molecular modelsSemantic proximity Read ↗

Proviral Latency, Persistent Human Immunodeficiency Virus Infection, and the Development of Latency Reversing AgentsSemantic proximity Read ↗

Assessing the impact of AGS-004, a dendritic cell-based immunotherapy, and vorinostat on persistent HIV-1 InfectionSemantic proximity Read ↗

Cellular and molecular mechanisms involved in the establishment of HIV-1 latencySemantic proximity Read ↗

Quantification of HIV-1 latency reversal in resting CD4 <sup>+</sup> T cells from patients on suppressive antiretroviral therapySemantic proximity Read ↗

Stable Latent HIV Infection and Low-level Viremia Despite Treatment With the Broadly Neutralizing Antibody VRC07-523LS and the Latency Reversal Agent VorinostatSemantic proximity Read ↗

Molecular control of HIV-1 postintegration latency: implications for the development of new therapeutic strategiesSemantic proximity Read ↗

Treatment with integrase inhibitor suggests a new interpretation of HIV RNA decay curves that reveals a subset of cells with slow integrationSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.